Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk to Seek Approval for Pill to Treat Diabetes in Young Patients
06:06am, Thursday, 23'rd Apr 2026
A late-stage trial showed that oral semaglutide significantly reduced blood sugar in 10- to 17-year-olds.
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins
05:30am, Thursday, 23'rd Apr 2026
Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.
Novo Nordisk's new weight-loss pill meets main goal in late-stage diabetes study
05:23am, Thursday, 23'rd Apr 2026
Novo Nordisk's oral GLP-1 drug met the main goal of a late-stage study in children and adolescents aged 10 to 17 years with type 2 diabetes, the drugmaker sai
PIONEER TEENS is the first clinical trial of an oral GLP-1 in children & adolescents 10–17 years with type 2 diabetes, addressing a significant unmet need
Biotech Investor Alex Karnal: GLP-1 Drugs Signal ‘Trillion-Dollar Revolution’ in Public Health
12:24pm, Wednesday, 22'nd Apr 2026
Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech companies before declaring on the Invest Like the Best podcast that "2025 was
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:56am, Wednesday, 22'nd Apr 2026
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Health insurers raise questions about Medicare program that will offer GLP-1s to seniors for $50
01:54pm, Tuesday, 21'st Apr 2026
Some health insurers are pushing back against a new program that will allow Medicare beneficiaries to pay $50 per month for GLP-1 medications for weight loss.
NVO's Etavopivat Hits Key Goals in Phase III Sickle Cell Disease Study
12:45pm, Tuesday, 21'st Apr 2026
Novo Nordisk's etavopivat meets phase III goals, cutting VOCs and boosting haemoglobin in sickle cell disease, with data backing a favorable safety profile.
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study
10:36am, Tuesday, 21'st Apr 2026
AGIO shares plunge after Novo Nordisk's strong sickle cell data raised doubts about mitapivat's competitiveness and approval prospects.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 21'st Apr 2026
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why Agios Pharmaceuticals Crashed 23% Today
12:19pm, Monday, 20'th Apr 2026
The market is concerned about the diminished market potential for Agios' mitapavit following today's newsflow.
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q1 Results?
11:11am, Monday, 20'th Apr 2026
Novo Nordisk's Q1 performance hinges on Ozempic and Wegovy sales, but rising competition, pricing pressure and muted 2026 guidance may temper growth momentum.
Novo Nordisk A/S - share repurchase programme
08:32am, Monday, 20'th Apr 2026
Bagsværd, Denmark, 20 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Cou
NVO DCF Analysis: Intrinsic Value $88 vs Price $41
06:34am, Monday, 20'th Apr 2026
On April 20, 2026, we present a DCF analysis for Novo Nordisk AS (NVO), a company that has experienced notable price performance fluctuations. Over the past wee
Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade
06:46pm, Friday, 17'th Apr 2026
The latest trading day saw Novo Nordisk (NVO) settling at $40.52, representing a -1% change from its previous close.
